Amadeus Capital Partners, the European technology investor, has invested $1.2 million early stage funding in TrialReach Ltd. (www.trialreach.com), an innovative search business whose website helps patients with any medical condition to explore, understand and access information on clinical trials anywhere in the world.

The funding will enable the company, headquartered in London, to develop its platform for patients, physicians and pharmaceuticals companies and to expand its services to multiple regions around the world, in native languages.
 
The explosion of information on the web and through social media has enabled patients to become much more deeply involved in managing their own diseases, but information about new treatments and clinical trials has remained, until now, obscure and inaccessible for the majority of those seeking help online. At the same time, thousands of new patients are needed daily for projects designed to test the effectiveness of new medical treatments and devices.
 
TrialReach’s unique website combines a specialised search engine, exclusive patient-friendly information and fast communication channels between patients and physicians to make clinical trials easy to find, easy to understand, and easy to access.
 
“Our strategy is based on empowering patients through content, tools and context, a formula that has revolutionised other sectors but has not yet been tried in clinical trials. Thousands of patients have signed up for studies through our website, and hundreds of them have been put in contact with relevant study investigators, following a strict triple-filter process”, said Pablo Graiver, TrialReach’s co-founder and CEO.
 
Amadeus Partner, Alex van Someren, said: “I was impressed from the outset by the importance of what TrialReach does in quickly connecting patients with treatments which could help them. Even better, the company is led by a team with real experience in building successful technology businesses. I’m genuinely excited about the potential for TrialReach to improve people’s lives, save trial sponsors time and money, and build a global business.”
 
TrialReach works closely with investigators and clinical trial sponsors, including Roche and Novartis, to create fresh online multimedia descriptions of the studies and user-friendly pre-screening questionnaires. The company’s product includes a feature that gives patients the option to forward their questions to healthcare professionals, usually the actual investigators of each study.
 
As Jessica Mann, MD PhD, co-founder and Chief Medical Advisor at TrialReach, noted: “The benefits that this set of tools and communications represents to patients and to the industry could be, quite literally, life-changing. Having experienced the patient recruitment problem for clinical trials first-hand for many years, I believe that TrialReach can offer a pioneering and durable solution that is both efficient and cost-effective.” 

About TrialReach

Headquartered in London, England, TrialReach is a global search and referral engine for clinical trials, dedicated to making clinical trials easy to find out about, understand, and get access to. TrialReach uses the latest online technologies and marketing tools to bridge the gap between patients wanting to take part in clinical trials and sponsors and investigators seeking to recruit participants. For more information about the company, visit www.trialreach.com
 
END
 
For further information, please contact: 
Chantal Ligertwood, PR for Amadeus, +44 (0)7976 229 210 chantal@ligertwood.net